Idelalisib Plus Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma: a Phase 2, Single-arm, Multicentric Study

FIL_GAUDEALIS

Single arm, prospective, multi-centric, phase II study. Patients with histologically confirmed follicular lymphoma, in need of a systemic approach and failing (i.e. with refractory disease \[no response or response lasting less than 6 months at any previous line of treatment\] or with a proven disease relapse) at least 2 previous lines of treatment, including any antibody directed against the CD20 antigen-containing chemotherapy, will undergo a combined chemo-free treatment with obinutuzumab and idelalisib.

2019-10-18

2021-04-29

2023-05-10

Terminated

Early phase I

5

Inclusion criteria Relapsed or refractory, histologically confirmed CD20-positive follicular non-Hodgkin's lymphoma, grade 1, 2 or 3a according to WHO 2017 classification. * Age 18 ≥ years * At least 2 prior systemic therapies for follicular lymphoma including both any antibody directed against the CD20 antigen and a chemotherapy combination. * Treatment indications, with the presence of at least one of the following: * bulky disease (nodal or extranodal mass - except spleen -more than 7 cm in its greater diameter or involvement of at least 3 nodal or extranodal sites, each with a diameter equal to or greater than 3 cm); * at least one B-symptom (fever \> 38°C of unclear etiology, night sweats, weight loss greater than 10% of body weight in the prior 6 months); * symptomatic splenomegaly; * compression syndrome (i.e. of orbits, ureters, gastrointestinal tract, biliary tract); * lymphoma-related cytopenias (hemoglobin \< 10 g/dL and/or platelets \< 100.000/mmc and/or neutrophils \< 1.500/mmc); * pleural or peritoneal serous effusions; * lactate dehydrogenase elevation. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2. * Adequate hematological function, unless abnormalities due to underlying disease, within 28 days prior to signing informed consent, defined as follows: neutrophils \> 1.500/mmc, platelets \> 75.000/mmc, hemoglobin \> 8,0 g/dL with transfusion independence. * Capacity and willingness to adhere to study visit schedule and specific protocol procedures. * Willingness to sign a written informed consent. * Compliance with effective contraception without interruption, from 28 days before treatment start up (i.e., during the screening phase) to 18 months after treatment discontinuation, agreeing not to donate the semen during treatment and for 18 months after discontinuation (if the patient is male), or to undergo ongoing pregnancy test during the course of the study (if the patient is female). * Patients must agree to undergo JPJ prophylaxis throughout the treatment period and 2-6 months thereafter (before consulting with Medical Monitor). Exclusion criteria Grade 3b follicular non-Hodgkin's lymphoma or evidence of transformation to high-grade non-Hodgkin's lymphoma. * Central nervous system or leptomeningeal involvement by lymphoma. * Major surgery (excluding any lymph node biopsy) within 28 days prior to signing informed consent. * Seropositivity for HBV or evidence of active infection (HBsAg positivity, or HBsAg negativity with positive anti-HBs/anti-HBc and detectable viral DNA load); if viral load is negative or undetectable, the patient is eligible, provided their HBsAg negativity. * Positive viral HCV RNA * Seropositivity for HIV, regardless of viral load. * Known history of drug induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, on-going extra-hepatic obstruction caused by cholelithiasis, cirrhosis of the liver or portal hypertension * Known history of drug induced pneumonitis * On-going inflammatory bowel disease * On-going alcohol or drug addiction * Life expectancy lower than 6 months. * Prior history of malignancies, other than follicular lymphoma, unless the patient has been free for at least 10 years (exceptions: localized non-melanoma skin cancer ad carcinoma in situ of the cervix). * Any of the following laboratory abnormalities: liver enzymes (AST/SGOT and/or ALT/SGPT) \> 2.5-fold the upper limit of normal (except of liver involvement by lymphoma); total bilirubin \> 1.5 mg/dL (except for patients with known Gilbert's disease or biliary tree compression by lymphoma masses); creatinine clearance \< 30 mL/min. * Uncontrolled intercurrent illness. * Known hypersensitivity or allergy to murine products or to any of the medicaments under investigation. * Pregnancy or breastfeeding, or unwillingness to comply with adequate contraception. * Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent the patient from signing the informed consent or which may place the patient at unacceptable risk if participating in the study. * Any evidence of ongoing bacterial, viral and fungal infection.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'Single arm: Regimen: GAUDEALIS q28 days\n\n* Obinutuzumab Dose: 1000 mg IV Day 1, 8, 15 (1st cycle)\n* Obinutuzumab Dose: 1000 mg IV Day 1 (2nd cycle onward)\n* Idelalisib Dose: 150 mg BID oral Daily (24 weeks) Obinutuzumab will be administered intravenously at a flat dose of 1000 mg on day 1, 8, 15, of the first cycle, then repeated on day 1 of each subsequent cycle, for 6 cycles in total (each cycle is completed in 28 days). Idelalisib will be given concomitantly with obinutuzumab on a daily 150 mg bid schedule orally and continuously (24 weeks).', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 5, 'type': 'ACTUAL'}}

2023-07-06